CORT INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Corcept Therapeutics Incorporated Investors

Core Viewpoint - The law firm Kirby McInerney LLP is reminding investors of Corcept Therapeutics Incorporated about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's securities during a specified class period [1]. Summary by Sections Lawsuit Details - The lawsuit alleges that Corcept misrepresented the strength of clinical trials supporting the New Drug Application (NDA) for relacorilant, claiming it was "powerful support" for FDA approval, while the FDA had raised concerns about the adequacy of clinical evidence [3]. - Corcept communicated confidence in the NDA submission, stating there were no anticipated impediments to approval, despite known risks regarding the NDA's approval status [3]. Impact of FDA Communication - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) indicating it could not assess a favorable benefit-risk profile for relacorilant without additional evidence, leading to a significant drop in share price by $35.40, or approximately 50.4%, from $70.20 to $34.80 [4]. - Following the end of the class period, the FDA released a redacted CRL detailing concerns about the clinical studies' sufficiency, resulting in a further decline in share price by $4.74, or approximately 10.6%, from $44.61 to $39.87 [5].